Feb. 13, 2018: 3 p.m. - 3:55 p.m.
While a majority of venture funding goes into development of oncology and rare disease treatments, the broader population with chronic diseases can also look forward to innovations from established biopharmas as well as smaller companies with promising new approaches. This session will highlight exciting pipelines for unmet need in NASH and ESRD and review the structural challenges of clinical development, as well as strategies for working with providers, payers, and patients on new medicines for high-cost chronic conditions.
Moderator: Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research
Steven J. Mento, PhD, President and Chief Executive Officer, Conatus Pharmaceuticals
Jim Tobin, PhD, Vice President, Scientific Innovation, Cardiovascular & Metabolic, Johnson & Johnson Innovation